Shopping Cart
- Remove All
Your shopping cart is currently empty
(±)-Darifenacin ((±)-UK-88525) is a potential inhibitor of p53-MDM2 interaction with anticancer activity for the study of overactive bladder, Alzheimer's disease and Parkinson's disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $49 | In Stock | |
| 10 mg | Preferential | In Stock | |
| 25 mg | Preferential | In Stock | |
| 1 mL x 10 mM (in DMSO) | $69 | In Stock |
| Description | (±)-Darifenacin ((±)-UK-88525) is a potential inhibitor of p53-MDM2 interaction with anticancer activity for the study of overactive bladder, Alzheimer's disease and Parkinson's disease. |
| Synonyms | (±)-UK-88525, (±)-UK88525 |
| Molecular Weight | 426.55 |
| Formula | C28H30N2O2 |
| Cas No. | 133033-93-9 |
| Smiles | O=C(N)C(C=1C=CC=CC1)(C=2C=CC=CC2)C3CN(CCC4=CC=C5OCCC5=C4)CC3 |
| Relative Density. | 1.192 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (187.55 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.74 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.